scholarly journals Consensus Statement on Hemostatic Management, Anticoagulation, and Antiplatelet Therapy in Liver Transplantation

2022 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Eva Montalvá ◽  
Manuel Rodríguez-Perálvarez ◽  
Annabel Blasi ◽  
Santiago Bonanad ◽  
Olga Gavín ◽  
...  
2018 ◽  
Vol 102 (5) ◽  
pp. 727-743 ◽  
Author(s):  
Michael Charlton ◽  
Josh Levitsky ◽  
Bashar Aqel ◽  
John OʼGrady ◽  
Julie Hemibach ◽  
...  

2014 ◽  
Vol 11 (10) ◽  
pp. 597-606 ◽  
Author(s):  
Glenn N. Levine ◽  
Young-Hoon Jeong ◽  
Shinya Goto ◽  
Jeffrey L. Anderson ◽  
Yong Huo ◽  
...  

2017 ◽  
Vol 101 (5) ◽  
pp. 945-955 ◽  
Author(s):  
Norah A. Terrault ◽  
Geoff W. McCaughan ◽  
Michael P. Curry ◽  
Edward Gane ◽  
Stefano Fagiuoli ◽  
...  

Cor et Vasa ◽  
2016 ◽  
Vol 58 (1) ◽  
pp. e175-e180 ◽  
Author(s):  
Petr Jakubec ◽  
Vítězslav Kolek ◽  
Dmitry Rakita ◽  
Ondřej Sobotík ◽  
Miloš Táborský ◽  
...  

Global Heart ◽  
2014 ◽  
Vol 9 (4) ◽  
pp. 457 ◽  
Author(s):  
Glenn N. Levine ◽  
Young-Hoon Jeong ◽  
Shinya Goto ◽  
Jeffrey L. Anderson ◽  
Yong Huo ◽  
...  

2014 ◽  
Vol 12 (8) ◽  
pp. 1183-1191 ◽  
Author(s):  
Meena A. Prasad ◽  
Laura M. Kulik

Orthotopic liver transplantation (OLT) offers the best chance for cure in the setting of unresectable hepatocellular carcinoma (HCC). A consensus statement recommends locoregional therapy (LRT) be considered in patients with HCC who are expected to wait more than 6 months for OLT to diminish dropout from the waiting list because of tumor progression. This article reviews LRT as a bridge to OLT in patients with HCC.


Sign in / Sign up

Export Citation Format

Share Document